Currenc Group, Inc. (CURR)
USD 1.56
(3.31%)
USD 1.56
(3.31%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -15.3 Million USD | -139.02% |
| 2022 | -6.4 Million USD | 59.44% |
| 2021 | -15.78 Million USD | 33.59% |
| 2020 | -23.77 Million USD | 4.52% |
| 2019 | -24.89 Million USD | -139.4% |
| 2018 | -10.4 Million USD | -27.61% |
| 2017 | -8.14 Million USD | -96.03% |
| 2016 | -4.15 Million USD | -159.35% |
| 2015 | -1.6 Million USD | -176.39% |
| 2014 | -580 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -897 Thousand USD | 70.44% |
| 2024 Q1 | -3.03 Million USD | -188.74% |
| 2023 Q2 | -987 Thousand USD | -372.25% |
| 2023 Q4 | 3.42 Million USD | 253.78% |
| 2023 FY | -15.3 Million USD | -139.02% |
| 2023 Q1 | -209 Thousand USD | 97.08% |
| 2023 Q3 | -2.22 Million USD | -125.33% |
| 2022 FY | -6.4 Million USD | 59.44% |
| 2022 Q1 | -5.15 Million USD | -18.2% |
| 2022 Q4 | -7.14 Million USD | -98.89% |
| 2022 Q3 | -3.59 Million USD | 62.65% |
| 2022 Q2 | -9.61 Million USD | -86.74% |
| 2021 FY | -15.78 Million USD | 33.59% |
| 2021 Q4 | -4.35 Million USD | -0.35% |
| 2021 Q1 | -3.17 Million USD | 80.75% |
| 2021 Q2 | -1.32 Million USD | 58.34% |
| 2021 Q3 | -4.34 Million USD | -228.77% |
| 2020 Q2 | -13.43 Million USD | -756.84% |
| 2020 FY | -23.77 Million USD | 4.52% |
| 2020 Q1 | 2.04 Million USD | 329.63% |
| 2020 Q4 | -16.47 Million USD | -498.95% |
| 2020 Q3 | -2.75 Million USD | 79.53% |
| 2019 Q3 | 2.2 Million USD | 117.43% |
| 2019 Q4 | -891 Thousand USD | -140.43% |
| 2019 FY | -24.89 Million USD | -139.4% |
| 2019 Q1 | -10.02 Million USD | -673.21% |
| 2019 Q2 | -12.64 Million USD | -26.12% |
| 2018 Q3 | -4.79 Million USD | -99.78% |
| 2018 Q2 | -2.4 Million USD | -26.32% |
| 2018 FY | -10.4 Million USD | -27.61% |
| 2018 Q4 | -1.29 Million USD | 72.98% |
| 2018 Q1 | -1.9 Million USD | -61.2% |
| 2017 Q3 | -1.8 Million USD | 28.82% |
| 2017 FY | -8.14 Million USD | -96.03% |
| 2017 Q1 | -2.62 Million USD | -16.38% |
| 2017 Q4 | -1.17 Million USD | 34.77% |
| 2017 Q2 | -2.54 Million USD | 3.02% |
| 2016 Q3 | -8352.00 USD | 21.71% |
| 2016 Q4 | -2.25 Million USD | -26858.48% |
| 2016 Q1 | -875.00 USD | 89.16% |
| 2016 Q2 | -10.66 Thousand USD | -1119.2% |
| 2016 FY | -4.15 Million USD | -159.35% |
| 2015 Q2 | 164.00 USD | 0.0% |
| 2015 Q4 | -8070.00 USD | -381.5% |
| 2015 Q3 | -1676.00 USD | -1121.95% |
| 2015 FY | -1.6 Million USD | -176.39% |
| 2014 FY | -580 Thousand USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 89.041% |
| PainReform Ltd. | -9.34 Million USD | -63.812% |
| Alvotech | -551.73 Million USD | 97.226% |
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 131.786% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | 181.509% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | -94.492% |
| Journey Medical Corporation | -3.85 Million USD | -297.263% |
| Dynavax Technologies Corporation | -6.38 Million USD | -139.577% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 92.685% |
| Bright Green Corporation | -13.12 Million USD | -16.598% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 136.483% |
| Embecta Corp. | 70.4 Million USD | 121.742% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -239.689% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -239.689% |
| SCYNEXIS, Inc. | 67.04 Million USD | 122.832% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | -87.507% |
| Silver Spike Investment Corp. | 7.34 Million USD | 308.533% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | -393.994% |
| Alpha Teknova, Inc. | -36.78 Million USD | 58.383% |
| Safety Shot Inc | -15.08 Million USD | -1.482% |
| Procaps Group, S.A. | 42.54 Million USD | 135.982% |
| Cosmos Health Inc. | -18.54 Million USD | 17.452% |
| Theratechnologies Inc. | -23.95 Million USD | 36.108% |
| Harrow Health, Inc. | -24.41 Million USD | 37.297% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | -216.578% |
| Biofrontera Inc. | -20.13 Million USD | 23.965% |
| DURECT Corporation | -27.62 Million USD | 44.59% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 1263.112% |
| Cronos Group Inc. | -73.96 Million USD | 79.305% |
| OptiNose, Inc. | -35.48 Million USD | 56.862% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 98.473% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 63.728% |
| RedHill Biopharma Ltd. | 23.91 Million USD | 164.001% |
| Organogenesis Holdings Inc. | 4.94 Million USD | 409.536% |
| Guardion Health Sciences, Inc. | 158.03 Thousand USD | 9785.667% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | -143.761% |
| Radius Health, Inc. | -25.79 Million USD | 40.652% |
| Universe Pharmaceuticals INC | -6.16 Million USD | -148.36% |
| ProPhase Labs, Inc. | -16.78 Million USD | 8.792% |
| Phibro Animal Health Corporation | 2.41 Million USD | 733.549% |
| Procaps Group S.A. | 42.54 Million USD | 135.982% |
| TherapeuticsMD, Inc. | -10.27 Million USD | -48.925% |
| Viatris Inc. | 54.7 Million USD | 127.983% |
| Rockwell Medical, Inc. | -8.43 Million USD | -81.379% |
| Aytu BioPharma, Inc. | -15.84 Million USD | 3.392% |
| SIGA Technologies, Inc. | 68.06 Million USD | 122.487% |
| Tilray Brands, Inc. | -244.98 Million USD | 93.752% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | 227.417% |
| Shineco, Inc. | -22.44 Million USD | 31.816% |
| PetIQ, Inc. | 2.13 Million USD | 818.28% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | -255.814% |
| Incannex Healthcare Limited | -18.45 Million USD | 17.078% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 106.13% |
| Alimera Sciences, Inc. | -20.13 Million USD | 23.969% |
| Assertio Holdings, Inc. | -331.94 Million USD | 95.389% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | -132.173% |
| Clever Leaves Holdings Inc. | -17.89 Million USD | 14.484% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 23.686% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 90.45% |
| Hempacco Co., Inc. | -13.12 Million USD | -16.612% |
| Talphera, Inc. | -18.39 Million USD | 16.799% |
| Alvotech | -551.73 Million USD | 97.226% |
| Eagle Pharmaceuticals, Inc. | 35.64 Million USD | 142.945% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 104.686% |
| Kamada Ltd. | 8.28 Million USD | 284.772% |
| Indivior PLC | 2 Million USD | 865.328% |
| Evoke Pharma, Inc. | -7.79 Million USD | -96.432% |
| Flora Growth Corp. | -57.03 Million USD | 73.163% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 23.686% |
| Evolus, Inc. | -61.68 Million USD | 75.186% |
| HUTCHMED (China) Limited | 100.78 Million USD | 115.188% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 111.128% |
| Akanda Corp. | -32.27 Million USD | 52.575% |